Zymedi Venture Capital
2 known investors
Zymedi develops precision medicine therapeutics targeting aminoacyl-tRNA synthetases (ARSs) to treat life-threatening diseases including cancer, immune disorders, and neurological conditions with unmet medical needs.
AI & Machine LearningBiotechMedical Devices